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Abstract
Background: An authentic survey of the transcript-level response of the diabetic endothelium in
vivo is key to understanding diabetic cardiovascular complications such as accelerated
atherosclerosis and endothelial dysfunction.
Methods: We used streptozotocin to induce a model of type I diabetes in transgenic mice that
express green fluorescent protein under the control of an endothelial-specific promoter (Tie2-
GFP) allowing rapid isolation of aortic endothelium. Three weeks after treatment, endothelial cells
were isolated from animals with blood glucose > 350 mg/dl. Aortae from the root to the renal
bifurcation were rapidly processed by mincing and proteolytic digestion followed by fluorescent
activated cell sorting to yield endothelial cell populations of >95% purity. RNA was isolated from
>50,000 endothelial cells and subjected to oligo dT amplification prior to transcriptional analysis on
microarrays displaying long oligonucleotides representing 32,000 murine transcripts. Five regulated
transcripts were selected for analysis by real-time PCR.
Results: Within replicate microarray experiments, 19 transcripts were apparently dysregulated by
at least 70% within diabetic mice. Up-regulation of glycam1, slc36a2, ces3, adipsin and adiponectin
was confirmed by real-time PCR.
Conclusion: By comprehensively examining cellular gene responses in vivo in a whole animal
model of type I diabetes, we have identified novel regulation of key endothelial transcripts that
likely contribute to the metabolic and pro-inflammatory responses that accompany diabetes.
Background
Diabetes increases mortality and morbidity in large part
due to cardiovascular events [1]. Vascular changes associ-
ated with diabetes include endothelial damage and dys-
function [2] that contribute to accelerated atherosclerosis
and the development of hypertension [3]. Diabetic
endothelial damage is likely multifactorial, involving
numerous stresses that impinge on the endothelial cells in
vivo. These include the generation of advanced glycation
end-products [4], the effects of dyslipidemia [5], the gen-
eration of reactive oxygen and nitrogen species [6], and
altered insulin signaling [7]. Many of the chronic
endothelial effects of diabetes will be reflected in tran-
scriptional regulation, either as a direct response to hyper-
glycemia and abnormalities of insulin signaling, or as a
secondary response to the effects of these stresses. An
assessment of the underlying in vivo transcriptional
changes associated with the earliest stages of insulin defi-
ciency will enhance our understanding of the endothelial
response in diabetes, and suggest pathways and candidate
genes that contribute to endothelial dysfunction and vas-
cular disease.
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Previous in vitro studies of the transcriptional response of
cultured endothelial cells to hyperglycemia have been per-
formed using macroarrays [8]. However, such an analysis
is not likely to capture the integrated organismal response,
which will include systemic effects of altered energy
metabolism, interaction among different cell types in the
vessel wall, and other global effects of altered insulin sig-
naling. By comprehensively examining endothelial gene
regulation in vivo in the diabetic animal, we expect to
derive a more robust and authentic view of the compo-
nents of pathways that are responsible for accelerated
atherogenesis, the most important cause of diabetic mor-
bidity and mortality.
Methods
Animals
Mice homozygous for the Tie2-GFP transgene (Tg
[TIE2GFP]287Sato, stock number 003658) were obtained
from Jackson labs (Bar Harbor, ME) and bred for these
experiments. Males were used at 6–10 weeks of age. Con-
trols were siblings of the treated animals. All procedures
were approved by the Institutional Animal Care and Use
Committee of the University of Hawaii.
Induction of diabetes
Following an overnight fast, a single 180 mg/kg dose of
streptozotocin (STZ, Sigma, St. Louis, MO) was injected
into the peritoneum. Control animals received injections
of sterile saline. Animals were allowed to feed ad libitum
on standard lab diet. 21 days after receiving injections,
glucose levels in cardiac blood were assessed by glucome-
ter (Accucheck, Becton Dickinson). STZ-injected animals
(with a glucose level >350 mg/dL) and saline-injected ani-
mals (with glucose <200 mg/dL) were processed on the
same day. In each of two independent experiments,
pooled cells from four experimental vs. four control mice
were collected 21 days after receiving injections.
Cell Isolation
Animals were euthanized by CO2 asphyxiation. The aortae
from the iliac bifurcation to the aortic root were excised by
dissection and freed of adherent tissue. The luminal blood
was removed and the aortas were sliced into 1 mm seg-
ments. The aortic segments pooled from 4 animals were
suspended in 5 ml of Dulbecco's PBS with dextrose 2 mg/
ml. The suspension was combined with 5 ml of pre-
warmed PBS containing 10 mg/ml type II collagenase
(Worthington), and 60 units/ml deoxyribonuclease I. The
suspension was agitated continuously at 37°C on a shak-
ing platform, and triturated 10 times every 10 minutes for
a total digestion period of 40 min to generate a single cell
suspension. The cell suspension was maintained at 0–4°C
throughout the remainder of the isolation, which lasted
2–3 hours total. The suspension was combined with 10
ml of 10% fetal bovine serum (FBS) in Dulbecco's Modi-
fied Eagle's Medium and cells were collected by centrifu-
gation and resuspended in 10 ml of PBS. This suspension
was then filtered through a sterile 40 um mesh filter to
remove undigested tissue fragments. Following centrifu-
gation, the pellet was resuspended in 0.3 ml PBS contain-
ing 0.5 mM EDTA, 30 U/ml deoxyribonuclease I, 3% FBS,
and 2 mg/ml dextrose. The suspension was once again fil-
tered through a 40 um mesh filter.
The resulting aortic cell suspensions were sorted using a
MoFlo from Dako Cytomation (Carpinteria, CA) or a Fac-
sAria from Becton Dickinson. Cells were excited by a 488
nm laser and GFP signals collected at 510 to 550 nm. Pos-
itive cells were collected directly into Trizol (Invitrogen,
Carlsbad CA) and processed according to the manufac-
turer's protocol. Glycogen was added to facilitate precipi-
tation of the sub-microgram quantities of RNA thus
obtained.
In addition to sorted endothelium, whole aortae from 4
diabetic and 4 control mice were individually collected 21
days after injections, rapidly frozen, extracted with Trizol,
and analyzed by real-time PCR.
RNA was purified further using the Micro RNEasy system
(Qiagen) according to the manufacturer's protocol. The
Qubit system (Invitrogen, Carlsbad CA) was used to fluor-
ometrically quantify the resultant RNA. Up to 20 ng RNA
isolated from cells was then subjected to two cycles of
amplification [9]. This produced 5–30 ug of cRNA for use
in microarray analysis and real-time PCR. Endothelial
RNA was also amplified with the SPIA system (Nugen, San
Carlos, CA) according to the manufacturer's protocol and
the resultant cDNA was analyzed by real-time PCR.
Microarray analysis
2 ug of cRNA from diabetic and control aortic cells were
labeled directly with Cy3 and Cy5 fluorophores with the
MicroMax labeling kit (Perkin Elmer, Waltham, MA)
according to the manufacturer's instructions and hybrid-
ized overnight to microscope slides containing the
Operon V3 long oligo array. Stringency washing at room
temperature was sequentially performed for ten minutes
in each of the following solutions: 2× SSC containing
0.1% SDS, 0.1× SSC containing 0.1% SDS, and finally,
0.1× SSC. Slides were scanned using the Genepix 4000B®
(Molecular Devices, Union City, CA). Replicate hybridiza-
tions were performed (with Cy3 and Cy5 dye-swapped)
and were analyzed with Genepix® and Acuity® software
from Molecular Devices.
The statistical analysis of microarray results was per-
formed using the functions available within Acuity®. Ini-
tial results were normalized using the ratio of medians
method and filtered to exclude those with any of the fol-Cardiovascular Diabetology 2008, 7:8 http://www.cardiab.com/content/7/1/8
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lowing characteristics: a percentage of saturated pixils >3,
a signal/noise ratio <3, a (regression ratio 635/532)2 < 0.6,
or a Genepix flag. Filtered results exhibiting up-regulation
(a log2 [fold change] >0.75) or down-regulation (log2
[fold change] <0.75) were tabulated. (A log2 [fold change]
of 0.75 corresponds to 1.7-fold on the linear scale). The
one sample t-test function in Acuity was applied to the
tabulated results.
Real-time PCR confirmation
Primer sequences are listed in Table 1. Superscript II (Inv-
itrogen) was used according to the manufacturer's instruc-
tions to generate cDNA from cRNA. All primer sets were
assessed by gel electrophoresis to confirm amplification
from endothelial cDNA of a single band of the expected
size. Primers were used to amplify product from cDNA
representing 5 ng of cRNA. PCR was run in triplicate with
SYBR® green fluorophore (Molecular Probes, Portland,
OR) in an Opticon™ device (MJ Research, Waltham, MA).
A standard two-phase reaction (95°C 15 sec, 60°C 1 min)
worked for all amplifications.
The relative expression level for each gene was interpo-
lated from a standard curve generated from a series of
cDNA dilutions at cycle times where Ct, the threshold
intensity, was clearly exceeded. In each real-time PCR run,
the abundance of GAPDH was assessed in parallel, and
expression values for genes of interest were calculated by
normalization to GAPDH as a loading control. Fold
changes represent the ratio of diabetic to control expres-
sion values. The statistical analysis of real-time PCR
results was performed using the t-test within Microsoft
Excel® to compare diabetic vs. control expression values.
Results
Microarray results have been placed in the GEO database
under series record GSE9072. Transcripts within the aortic
endothelium dysregulated by at least 70% in response to
the type I diabetic model are shown in fig. 1. The average
microarray-based fold change, reference sequence iden-
tity, and p-value are included in Table 2. Five transcripts
displaying a high level of dysregulation in replicate array
hybridizations were chosen for analysis by real-time PCR.
As shown in fig. 2, there is concordance between the
measurement of the diabetic response by microarray vs.
real-time PCR.
Changes in mRNA abundance 21 days after streptozotocin  exposure as determined by microarray analysis Figure 1
Changes in mRNA abundance 21 days after strepto-
zotocin exposure as determined by microarray anal-
ysis. This heat map shows 23 features found consistently 
dysregulated by greater than 1.7-fold in diabetic vs. control 
endothelium. Green indicates down-regulation and red indi-
cates up-regulation. Each column represents a single micro-
array analysis. Columns 1–2 and columns 3–4 display the 
results of separate experiments. Column 2 and 4 represent 
dye-reversed arrays of 1, and 3, respectively.
Table 1: Real-time PCR primer sequences
Transcript RefSeq ID Forward Reverse
Adiponectin NM_009605 TCAGTGGATCTGACGA CACCA AGCTTGCAACAGTAG CATCCTG
Ces3 NM_053200 AGAGCCCTGGAGCTTC GTG GAGCACATAGGCGGG TAGGAG
Adipsin NM_013459 GCAGTGGGTGCTCAGT GCT TCGTCATCCGTCACTC CATC
Slc36a2 NM_153170 CCGCTCTTCTTTGGAAC AGC GACCACACCGATGCTT TCAA
Glycam1 NM_008134 CACAGATGCCATTCCAG CTG TCACTGGTGTAGCTGG TGGGCardiovascular Diabetology 2008, 7:8 http://www.cardiab.com/content/7/1/8
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Enzymatically isolated preparations of adipose stromal
cells exhibiting contamination by small immature adi-
pocytes has been reported [10]. In our studies, we con-
sider contamination of the sorted endothelium product
by small adipose cells to be unlikely, due to the aortic
source tissue and high degree of purification achieved by
FACS. Moreover, in results not shown, SVEC cells, an SV-
40 immortalized line of endothelial cells, do indeed
express adiponectin as determined by real-time PCR.
Dysregulation of glycam1 and adiponectin was confirmed
in a third independent experiment in which an alternative
amplification system, the SPIA system, was employed to
amplify RNA directly into cDNA. This endothelial regula-
tion, shown in fig. 3, was determined using real-time PCR
and is in agreement with the microarray and real-time
analysis shown in fig. 2. Also shown in fig. 3, a similar
analysis of whole aortic tissue from diabetic mice reveals
much less dysregulation. The smaller response of Glycam
1 and adiponectin within diabetic aorta vs. the FACS-
sorted product most likely reflects the relatively low pro-
portion of endothelial cells in whole aorta.
Discussion
In our survey of the endothelial response to a model of
type I diabetes in mice, two categories of transcripts pre-
dominate – those related to metabolic function and those
related to inflammation.
The alterations in metabolic function and insulin signal-
ing in diabetes are reflected in the endothelial transcrip-
Comparison of real-time PCR and microarray results Figure 2
Comparison of real-time PCR and microarray 
results. Combined real-time PCR and microarray results of 
selected genes uncovered by the microarray analysis 
described in table 1. * indicates a p-value < .05, ** indicates a 
p-value < .005.
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Table 2: Average expression fold change in diabetic vs. control endothelium
Name Operon ID RefSeq ID Fold Change P-value
ApoD (apolipoprotein D) M200000796 NM_007470 2.1 0.02
Adiponectin M200001531 NM_009605 8.1 0.01
Cxcl2 M200002070 NM_009140 2.8 0.19
Glutathione peroxidase 3 M200002493 NM_001083929 2.6 0.28
Hsdl2 (hydroxysteroid dehydrogenase-like 2) M200005344 NM_024255 2.3 0.01
Coq10b (coenzyme Q10 homolog B) M200005601 NM_026424 2.3 0.18
Gdf15 (growth/differentiation factor 15) M200007081 NM_011819 3.3 0.06
Acta1 (alpha actin, skeletal muscle) M200013335 NM_009606 1.8 0.08
Oit3 (oncoprotein-induced transcript 3) M300001065 NM_010959 0.4 0.13
Adipsin M300002011 NM_013459 10.9 0.03
Adipsin M300002012 NM_013459 9.5 0.03
Slc36a2 M300002100 NM_153170 4.1 0.02
Theg (testicular haploid expressed gene) M300002133 NM_011583 3.6 0.01
Ifi27 (interferon alpha-inducible protein 27) M300002619 NM_029803 2.8 0.05
Mcpt5 (mast cell chymase) M300003152 NM_010780 2.7 0.13
Glycam1 M300003316 NM_008134 10.3 0.02
Ces3 (carboxylesterase 3) M300007868 NM_053200 5.9 0.08
Chi3l (chitinase 3-like 3 or -4) M300012867 NM_009892 NM_145126 2.9 0.01
Unknown M300014207 NM_177039 2.3 0.08
Iap (IgE binding protein) M300014963 NM_010490 0.4 0.11
Olfr695 (olfactory receptor 695) M300017077 NM_146598 2.0 0.20
Unknown M300019951 XM_001475202 0.4 0.08
Unknown M300022328 -- 2.1 0.06Cardiovascular Diabetology 2008, 7:8 http://www.cardiab.com/content/7/1/8
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tome's response. Adipsin has previously been shown to be
elevated in rats exposed to STZ-induced diabetes [11].
Adipsin and complement factor B assemble to enzymati-
cally cleave complement factor C3 to C3a-des-arg/ASP
(acylation stimulating protein) which stimulates triglycer-
ide production in adipose tissue. Mice deficient in C3
exhibit resistance to diet-induced obesity [12]. We specu-
late that the endothelial up-regulation of adipsin reflects
adaptive responses to fat utilization as the prime energy
source in insulin-deficient animals. Apolipoprotein D is a
potential carrier molecule for lipids and hormones [13].
Hsdl2 is potentially involved in intracellular lipid trans-
port. Up-regulation of Slc36a2, an amino acid transporter
[14], potentially reflects utilization of amino acids as
alternative energy substrates. Our finding of increased adi-
ponectin (a molecule that can enhance insulin signaling
[15]) in our Type I model of diabetes contrasts with
decreased adiponectin in human Type II diabetes[16].
Up-regulation of Cxcl2, a chemokine capable of inducing
leukocyte rolling and extravasation in vivo [17] may con-
tribute to immune-mediated vascular damage and the ini-
tiation of atherosclerotic lesions. We observed prominent
up-regulation of Glycam 1, a glycoprotein expressed
within the lymph node venous endothelium of mice[18].
Glycam1 can participate in lymphocyte attachment and
extravasation into the blood vessel wall [19], and plasma
levels of this molecule are found up-regulated in inflam-
mation [20]. We observed increased Mcpt5, a mast cell
protease considered to be a key regulator of angiotensin II
expressed in cardiac endothelium [21]. Interestingly,
Mcpt5 has been shown to be up-regulated in smooth mus-
cle cells upon exposure to advanced glycation endprod-
ucts formed during diabetes [22]. Our observed increase
in Gpx3 within the diabetic endothelium parallels
increased Gpx3 within heart observed in a nearly identical
model of streptozotocin-induced diabetes in mice [23].
Chi3l3 or -4, are members of a group of closely related,
non-functional chitinases exhibiting increased levels dur-
ing inflammation [24]. Ifi27, also known as Isg12, is a
small intracellular protein induced by interferon signaling
or other stress [25].
Conclusion
Overall, our transcriptional analysis of the endothelium
in an in vivo model of type I diabetes reveals the regula-
tion of previously unsuspected genes. The products of
these genes participate in basic responses of the vascula-
ture to the combined effects of hyperglycemia, hypoin-
sulinemia, and inflammation associated with diabetes.
These findings implicate pathways that are likely to be
important in diabetic vascular pathology.
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